Intralesional bevacizumab as an adjuvant approach to recurrent respiratory papillomatosis: A prospective study on different treatment protocols
PLOS One · 2026
DOI: 10.1371/journal.pone.0342749 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Hanna Klimza und 3 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology Department with the Paediatric Otolaryngology Subunit, Regional Specialist Hospital, Wroclaw, Poland. Hauptthemen laut MEDLINE: Bevacizumab, Respiratory Tract Infections, Papillomavirus Infections, Antineoplastic Agents, Immunological. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Adjuvant intralesional administration of bevacizumab has shown promising effects in the management of recurrent respiratory papillomatosis (RRP). However, the optimal therapeutic parameters remain undefined. This prospective study aimed to compare the efficacy of two distinct intralesional bevacizumab administration protocols following surgical resection of RRP.
Methods
Between 15/09/2023 and 31/12/2024, adult patients with RRP were enrolled in a prospective research study. Participants were allocated to one of two bevacizumab administration protocols, delivered intralesional during direct microlaryngoscopy and CO₂ laser excision. Disease severity was assessed using the Derkay, Dikkers and Numerical scoring systems, as well as the Voice Handicap Index (VHI), at baseline and at 8-week intervals.
Results
Both treatment regimens were associated with reduction in disease burden and improved voice outcomes. No statistically significant differences in disease control were observed between the two administration protocols.
Conclusion
This study indicates that both dosing regimens of bevacizumab were effective as an adjunctive therapy of recurrent respiratory papillomatosis. The higher intralesional doses of bevacizumab are relatively safe and well tolerated in adult patients with laryngeal RRP. Further studies with extended follow-up are warranted to define long-term efficacy and optimal dosing strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Otolaryngology Department with the Paediatric Otolaryngology Subunit, Regional Specialist Hospital, Wroclaw, Poland.
- Faculty of Law and Administration, Jagiellonian University, Kraków, Poland.
- Department of Surgical Clinical Sciences, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland.
- Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
ORCID-Profile: Bartosz Zakrzewski, Andrzej Porębski
Zitieren
APA
Klimza, H., Zakrzewski, B., Porębski, A., & Wierzbicka, M. (2026). Intralesional bevacizumab as an adjuvant approach to recurrent respiratory papillomatosis: A prospective study on different treatment protocols. PLOS One. https://doi.org/10.1371/journal.pone.0342749
Vancouver
Klimza H, Zakrzewski B, Porębski A, Wierzbicka M. Intralesional bevacizumab as an adjuvant approach to recurrent respiratory papillomatosis: A prospective study on different treatment protocols. PLOS One. 2026. doi:10.1371/journal.pone.0342749
BibTeX
@article{Klimza2026,
author = {Klimza, Hanna and Zakrzewski, Bartosz and Porębski, Andrzej and Wierzbicka, Małgorzata},
title = {Intralesional bevacizumab as an adjuvant approach to recurrent respiratory papillomatosis: A prospective study on different treatment protocols},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0342749}
}
EUVIMED